Real-world use of insulin degludec/liraglutide (IDegLira) significantly improves glycaemic control in patients with Type 2 diabetes

被引：0
|
作者：
Feher, M. [1 ]
Price, H. [2 ]
Schultes, B. [3 ]
Prager, R. [4 ]
Phan, T. M. [5 ]
Thorsted, B. L. [6 ]
Bluher, M. [7 ]
机构：
[1] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[2] Southern Hlth NHS Fdn Trust, Bournemouth, Dorset, England
[3] ESwiss Med & Surg Ctr, Internal Med, St Gallen, Switzerland
[4] Hietzing Hosp, Dept Metab Disorders & Nephrol, Vienna, Austria
[5] Novo Nordisk Reg Europe Pharmaceut AS, Copenhagen, Denmark
[6] Novo Nordisk AS, Global Market Access, Soborg, Denmark
[7] Univ Leipzig, Dept Med, Leipzig, Germany
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P391
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [21] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Young-A Heo
    Drugs & Therapy Perspectives, 2020, 36 : 219 - 229
  • [22] Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
    Vilsboll, Tina
    Vora, Jiten
    Jarlov, Henrik
    Kvist, Kajsa
    Blonde, Lawrence
    CLINICAL DRUG INVESTIGATION, 2016, 36 (04) : 293 - 303
  • [23] Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
    Tina Vilsbøll
    Jiten Vora
    Henrik Jarlov
    Kajsa Kvist
    Lawrence Blonde
    Clinical Drug Investigation, 2016, 36 : 293 - 303
  • [24] Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes
    Vedtofte, Louise
    Knop, Filip K.
    Vilsboll, Tina
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 387 - 396
  • [25] Insulin degludec/liraglutide (IDegLira) improves patient-reported outcomes in subjects with type 2 diabetes uncontrolled on insulin glargine plus metformin: DUALV
    Lingvay, I.
    Manghi, F. C. Perez
    Garcia-Hernandez, P. A.
    Norwood, P.
    Jarlov, H.
    Kongso, J. H.
    Brod, M.
    DIABETOLOGIA, 2015, 58 : S400 - S400
  • [26] Novel combination of insulin degludec and liraglutide (IDegLira) is efficacious across the range of disease progression in type 2 diabetes
    Rodbard, H. W.
    Buse, J. B.
    Woo, V. C.
    Vilsboll, T.
    Langbakke, I.
    Korsholm, L.
    Gough, S.
    DIABETOLOGIA, 2014, 57 : S338 - S339
  • [27] Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes
    Sarah L. Greig
    Lesley J. Scott
    Drugs, 2015, 75 : 1523 - 1534
  • [28] Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes
    Greig, Sarah L.
    Scott, Lesley J.
    DRUGS, 2015, 75 (13) : 1523 - 1534
  • [29] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Kondo, Yuichiro
    Katamine, Aki
    Shimizu, Mika
    Kubota, Ryo
    Suda, Rika
    Babazono, Tetsuya
    DIABETOLOGY INTERNATIONAL, 2024, 15 (02) : 237 - 243
  • [30] Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
    Paola Ponzani
    Cesare Berra
    Alessandra Di Lelio
    Paola Del Sindaco
    Chiara Di Loreto
    Francesco Reggiani
    Giuseppe Lucisano
    Maria Chiara Rossi
    Diabetes Therapy, 2018, 9 : 2209 - 2218
12345